SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (452)12/17/2018 10:53:32 AM
From: scaram(o)uche  Read Replies (1) of 684
 
Wish I'd have seen that list over the weekend.

:-(

My eye returns to CLDX. Anyone see any gross deficiencies, other than a history of moving slowly toward failure?

I am intrigued by the trial combining flt3 ligand with anti-CD40. The concept is to expand dendritic cells and then activate them. Not much in literature supporting the concept. One study shows that the combo works in a mouse model, another shows that flt3 ligand, unlike GMCSF, expands traditional dendritic cells.

These are the live trials.....

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News